NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.07 0.00 (0.00%) As of 09/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Sangamo Therapeutics Stock (NASDAQ:SGMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.07▼$0.0752-Week Range$0.06▼$0.77VolumeN/AAverage Volume8.10 million shsMarket Capitalization$30.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingReduce Company Overview Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines for serious diseases. The company’s platform is based on zinc finger proteins, which it uses to design gene-editing nucleases, gene-regulation technologies and cell therapies intended to modify disease-related genetic activity. Sangamo has developed investigational programs in areas including genetic, neurological and immune-mediated diseases. Its pipeline has included ST-920, an experimental gene therapy for Fabry disease, as well as programs using gene regulation and cell engineering approaches. These candidates remain subject to clinical testing and regulatory review, and the company does not currently market an approved product. Founded in 1995, Sangamo is headquartered in Brisbane, California. The company has advanced its programs through internal research and collaborations with larger pharmaceutical and biotechnology organizations, supporting development efforts for patients in the United States and international markets. Sandy Macrae has served as the company’s chief executive officer since 2016.AI Generated. May Contain Errors. Read More Sangamo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreSGMO MarketRank™: Sangamo Therapeutics scored higher than 19% of companies evaluated by MarketBeat, and ranked 835th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingSangamo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.Upside PotentialSangamo Therapeutics has a consensus price target of $5.50, representing about 7,332.4% upside from its current price of $0.07.Amount of Analyst CoverageSangamo Therapeutics has received no research coverage in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SGMO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.92% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMO Stock News HeadlinesSangamo Therapeutics Advances Bankruptcy Asset Sale ProcessJuly 20, 2026 | tipranks.comSangamo Therapeutics Inc SGMOJuly 7, 2026 | morningstar.comMSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.September 18 at 1:00 AM | Behind the Markets (Ad)Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and AstellasJune 24, 2026 | markets.businessinsider.comSangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assetsJune 24, 2026 | seekingalpha.comSangamo Therapeutics files for Chapter 11 bankruptcyJune 24, 2026 | msn.comSangamo Therapeutics Initiates Chapter 11 and Asset SalesJune 23, 2026 | tipranks.comSangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for StakeholdersJune 8, 2026 | globenewswire.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.42 on January 1st, 2026. Since then, SGMO stock has decreased by 82.4% and is now trading at $0.0740. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its earnings results on Thursday, November, 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.08. The biopharmaceutical company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $34.40 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 2,662.06% and a negative net margin of 310.81%. Read the conference call transcript. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), abrdn Asia-Pacific Income Fund (FAX) and Tesla (TSLA). Company Calendar Last Earnings11/06/2025Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SGMO's financial health is in the Red zone, according to TradeSmith. SGMO has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Price Target for Sangamo Therapeutics$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+7,332.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$122.93 million Net Margins-310.81% Pretax Margin-312.25% Return on Equity-2,662.06% Return on Assets-132.12% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$39.55 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-1.85Miscellaneous Outstanding Shares414,289,000Free Float397,291,000Market Cap$30.66 million OptionableOptionable Beta1.30 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SGMO) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIs This the New Normal for Gold?Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
